Clinical Trials Logo

Clinical Trial Summary

A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals. HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05373459
Study type Observational
Source Hong Kong Sanatorium & Hospital
Contact
Status Completed
Phase
Start date May 16, 2022
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Recruiting NCT05185817 - Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients Phase 2
Not yet recruiting NCT04876885 - The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations N/A
Active, not recruiting NCT05571657 - COVID-19 Booster Dose Reminder/Recall for Adolescents N/A
Completed NCT04888793 - Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Completed NCT04881396 - Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Recruiting NCT04871165 - Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
Active, not recruiting NCT05293665 - Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine Phase 3
Active, not recruiting NCT05405283 - Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Phase 3
Recruiting NCT05508477 - UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study) Phase 3
Recruiting NCT05471635 - Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
Recruiting NCT06282692 - INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old Phase 3
Completed NCT05406908 - Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases Phase 4
Recruiting NCT04895007 - Comparative Evaluation of Covid-19 Vaccines Response
Recruiting NCT05831826 - Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
Recruiting NCT05096260 - Getting to Yes, Michigan! (G2YMI) N/A
Completed NCT04962906 - Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes Phase 2
Active, not recruiting NCT05027672 - Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. Phase 2